Physician profile
Heather Doolittle
NPI 1629643317
$7,525.09
in general payments reported to CMS, 2019-2025
31 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,742 · 2023: $2,526 · 2024: $1,664 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,782.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,273.93 | 2022-2025 | |
| Lilly USA, LLC | $945.45 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $812.51 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $762.35 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $668.49 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $550.72 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $498.97 | 2022-2025 | Evenity, Otezla, Repatha |
| Pharmacosmos Therapeutics INC. | $315.18 | 2023-2025 | Monoferric |
| Janssen Pharmaceuticals, INC | $243.53 | 2022-2023 | Xarelto |
| Pfizer INC. | $208.14 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.54 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $173.11 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $153.09 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $130.03 | 2025 | Rexulti |
| Exact Sciences Corporation | $85.55 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $76.20 | 2022 | |
| Neurocrine Biosciences, INC. | $75.90 | 2022-2025 | Ingrezza |
| Sumitomo Pharma America, INC. | $48.90 | 2023 | Gemtesa |
| Abbott Laboratories | $43.94 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $32.09 | 2023-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.07 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $32.07 | 2022-2023 | |
| Lundbeck LLC | $30.62 | 2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $30.06 | 2024-2025 | Trintellix |
| Corium, LLC | $28.69 | 2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $21.96 | 2025 | Jornay Pm |
| Dexcom, INC. | $19.90 | 2025 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $16.48 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.46 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $2.16 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Doolittle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.